Amani uses cutting-edge research to break down barriers and provide people with severe mental illness with efficient treatments.
Amani Therapeutics has raised $25.0M in total funding. The most recent round was Series A. The last funding was announced in March 2026.
Amani Therapeutics's investors include RTW Investments.
Amani Therapeutics is headquartered in New York, United States.
Amani uses cutting-edge research to break down barriers and provide people with severe mental illness with efficient treatments.
Amani Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Amani Therapeutics — Funding & Investors." VCBacked, March 23, 2026, https://www.vcbacked.co/company/amani-therapeutics. Accessed August 23, 2026.
VCBacked. (2026). Amani Therapeutics — Funding & Investors. Retrieved August 23, 2026, from https://www.vcbacked.co/company/amani-therapeutics
{{cite web |title=Amani Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/amani-therapeutics |website=VCBacked |access-date=August 23, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated